- Home
- OMH vs SNGX Comparison
OMH vs SNGX Comparison
Compare OMH & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMH
- SNGX
- Stock Information
- Founded
- OMH 2015
- SNGX 1987
- Country
- OMH Singapore
- SNGX United States
- Employees
- OMH N/A
- SNGX N/A
- Industry
- OMH Real Estate
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- OMH Finance
- SNGX Health Care
- Exchange
- OMH Nasdaq
- SNGX Nasdaq
- Market Cap
- OMH 9.2M
- SNGX 9.6M
- IPO Year
- OMH 2023
- SNGX 1987
- Fundamental
- Price
- OMH $0.39
- SNGX $3.51
- Analyst Decision
- OMH Strong Buy
- SNGX
- Analyst Count
- OMH 1
- SNGX 0
- Target Price
- OMH $1.50
- SNGX N/A
- AVG Volume (30 Days)
- OMH 164.8K
- SNGX 56.4K
- Earning Date
- OMH 11-29-2024
- SNGX 11-08-2024
- Dividend Yield
- OMH N/A
- SNGX N/A
- EPS Growth
- OMH N/A
- SNGX N/A
- EPS
- OMH N/A
- SNGX N/A
- Revenue
- OMH $5,390,607.00
- SNGX $364,183.00
- Revenue This Year
- OMH $101.90
- SNGX N/A
- Revenue Next Year
- OMH $38.34
- SNGX $76.64
- P/E Ratio
- OMH N/A
- SNGX N/A
- Revenue Growth
- OMH 25.77
- SNGX N/A
- 52 Week Low
- OMH $0.32
- SNGX $1.83
- 52 Week High
- OMH $6.00
- SNGX $32.00
- Technical
- Relative Strength Index (RSI)
- OMH 47.37
- SNGX 49.14
- Support Level
- OMH $0.36
- SNGX $3.50
- Resistance Level
- OMH $0.46
- SNGX $3.74
- Average True Range (ATR)
- OMH 0.05
- SNGX 0.20
- MACD
- OMH 0.00
- SNGX 0.01
- Stochastic Oscillator
- OMH 51.72
- SNGX 47.37
About OMH Ohmyhome Limited
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, Property Management Services, and revenue from emerging and other services.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).